COMP <GO>
ARQT vs EWTX // EV/EBITDA & P/E VALUATION
Arcutis Biotherapeutics Inc. (NASDAQ) VS. Edgewise Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ARQT 7
— EWTX 4
■ METRIC PARITY
LAST: $31.26 (-2.53%) • MKT CAP: $4.03B
valuation
—
LAST: $38.11 (-2.03%) • MKT CAP: $4.22B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. EWTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | EWTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | -31.90% | +28.90 | ARQT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | -3.41% | +3.25 | ARQT | /fcf-yield <GO> |
| Operating Margin | -3.30% | -16.20% | +12.90 | ARQT | /operating-margins <GO> |
| Net Profit Margin | -4.30% | 0.00% | -4.30 | EWTX | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | -1.10% | +92.40 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 26.00 | -18.22 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 3/9 | +3.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 45.7 | +20.30 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.10 | -0.10 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 25.0x | -1.00 | ARQT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $4.22B | -$193.8M | EWTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | EWTX REV | ARQT GROSS % | EWTX GROSS % | ARQT FCF | EWTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $535.9M | 90.2% | — | -$6.3M | -$144.1M |
| FY 2024 | $196.5M | $444.7M | 90.3% | — | -$112.3M | -$110.3M |
| FY 2023 | $59.6M | $320.2M | — | — | -$249.7M | -$91.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
EWTX // BETA 1.10